mardi 27 juin 2017

Onco Actu du 27 juin 2017


2. Etiologie

Night shift work may stop body repairing daily damage to DNA and trigger cancer, study suggests [The Telegraph]

2.6 Etiologie - Environnement

California to list glyphosate as cancer-causing; Monsanto vows fight [Reuters]

3.1.1 Tabac - e-cigs

Vaping teens more likely to take up regular cigarettes [Reuters]

4. Dépistage, diagnostic et pronostic

The Lab Says It’s Cancer. But Sometimes the Lab Is Wrong. [NY Times]

4.1 Dép., diag. & prono. - Prostate

The New Health Care: The ABCs and Ds of Whether to Get Prostate Cancer Screening [NY Times]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Fast, precise cancer care is coming to a hospital near you [Wired]

4.2 Dép., diag. & prono. - Génome

Whole genome sequencing not ready for routine use: study [Reuters]

You can get your whole genome sequenced. But should you? [Wired]

Routine DNA Sequencing May Be Helpful And Not As Scary As Feared [NPR]

In healthy patients, genome sequencing raises alarms while offering few benefits [STAT]

DNA Testing Reveals the Chance of Bad News in Your Genes [MIT Technology Review]

One in five 'healthy' adults may carry disease-related genetic mutations [Science]


5.10 Traitements - Essais

New bladder cancer therapy to start clinical trials [Cancer Research UK]

5.12 Immunothérapies

Using ‘sticky’ nanoparticles, researchers develop new strategy to boost body’s cancer defenses [UNC]

5.2 Pharma

Can Adcetris' narrow beat in new trial win a new FDA nod? Seattle Genetics, Takeda hope so [FiercePharma]

Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma [Forbes]

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma [Seattle Genetics]

Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial [Reuters]

5.3 Traitements - FDA, EMA, NICE...

EMA Offers New EudraVigilance Checklist for Sponsors, MAHs [RAPS]

5.4 Traitements - Economie

EU tests limits of drug pricing freedom in landmark probe [Reuters]

5.9.3 EHA

ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia [ImmunoGen]

6. Lutte contre les cancers

Precision Medicine: the Promise vs. the Reality [University of Michigan]

Speaking The Same Language: The ESMO Glossary In Personalised Medicine [ESMO]

Hunted, haunted, stateless and scared: the stories of refugee scientists [Nature]

6.10 Politiques

Experts warn of chaotic fallout from post-Brexit nuclear plan [The Times]

6.11 Patients

Developing a Survivorship Taxonomy That Puts People First [ASCO Connection]

6.3 Associations/Fondations

Launching the Biden Cancer Initiative [BDI]

AACR Applauds Launch of Biden Cancer Initiative [AACR]

6.4 Médico-éco

Medicaid cuts linked to later breast cancer diagnosis [Reuters]

6.9 Controverses

The NIH is squandering an opportunity to fund more researchers [STAT]